Eradivir
Eradivir is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Eradivir.
Eradivir is a company.
Key people at Eradivir.
Key people at Eradivir.
Eradivir Inc. is a privately held, clinical-stage biotechnology company founded in 2020 and headquartered in West Lafayette, Indiana. It develops small-molecule immunotherapies using its proprietary BAiT (Bispecific Antigenic immuno-Therapy) platform, which binds to diseased cells to guide the immune system for rapid, selective destruction, combining small-molecule simplicity with antibody-like efficacy[1][2][3]. The company targets viral infections like influenza and RSV, with its lead product EV25 in Phase 2 trials for influenza, showing preclinical superiority over standard care by reducing live virus to undetectable levels within 24 hours[1][2][5]. EV25 serves patients with influenza infections, solving the problem of ineffective antivirals against diverse strains by recruiting innate immunity via anti-hapten antibodies[2][5]. Growth momentum includes a $10-10.25 million Series A funding round closed recently to complete the EV25 Phase 2a challenge study (results expected August 2025) and advance EV148 for RSV[3][5].
Eradivir was founded in March 2020 to commercialize immunological innovations from Philip Low, Purdue University's Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry, who serves as Chief Scientific Officer and board member[1][4][5]. Low disclosed the BAiT platform technology to Purdue's Office of Technology Commercialization, which licensed it exclusively to Eradivir after filing patents[5]. CEO Martin Low leads operations, while key executives include CTO (presenting at BIO 2025) and Chief Scientific Officer Ray Schinazi, a nucleoside chemistry pioneer behind FDA-approved HIV, HBV, and HCV drugs like sofosbuvir[1][4]. Gerald, with CMC expertise from Reata Pharmaceuticals (including FDA approval of Skyclarys), handles manufacturing[4]. Early traction came from preclinical data on EV25 outperforming influenza standards, enabling the recent Series A from insiders, Purdue affiliates, and small investors aligned with reinvestment goals[3][5].
Eradivir rides the trend toward immune-guided therapies for antivirals, addressing gaps in current treatments amid rising viral threats like influenza and RSV, which cause millions of hospitalizations annually[1][2]. Timing aligns with post-pandemic demand for broad-spectrum, rapid-acting antivirals—EV25's 24-hour efficacy fills needs unmet by vaccines or Tamiflu-like drugs[2][5]. Market forces favor it: small-molecule scalability reduces costs vs. antibodies; Purdue licensing provides IP strength; funding from aligned insiders supports agility in a biotech sector wary of big-pharma delays[3][5]. By targeting innate immunity, Eradivir influences the ecosystem, potentially enabling "off-the-shelf" cures for viruses and cancers, reinvesting proceeds into Purdue-linked discoveries[2][5].
Phase 2a EV25 results in August 2025 mark the key near-term catalyst, potentially validating human efficacy and unlocking Phase 2b/3 trials or partnerships[1][3]. Pipeline trends like RSV (EV148) and oncology extensions position Eradivir for multi-indication growth, shaped by AI-driven discovery and resilient supply chains[3][4]. Influence may evolve via licensing deals or acquisitions, amplifying its BAiT platform's role in precision immunotherapy—echoing its founding mission to safely harness immunity against intractable diseases[2][5].